Top

Bijblijven

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in:

10-01-2017

Diagnostiek, behandeling en nazorg van het basaalcelcarcinoom

Auteurs: Drs. Esther Burkink, Dr. Nicole W. J. Kelleners-Smeets

Gepubliceerd in: Bijblijven | Uitgave 2/2017

Samenvatting

Het basaalcelcarcinoom (BCC) is de meest voorkomende vorm van kanker in Nederland (80% van alle huidkankers). Het aantal BCC’s is in ruim 35 jaar tijd enorm toegenomen en deze stijging zet door. Geschat wordt dat in 2020 de incidentie zelfs zal stijgen naar 234 per 100.000 persoonsjaren voor mannen en 226 per 100.000 persoonsjaren voor vrouwen. Vooral de vergrijzing in combinatie met de toegenomen hoeveelheid zonlichtexpositie vergroot het risico op het krijgen van een BCC. Dit artikel geeft een overzicht van de diagnostische procedures en de verschillende behandelmogelijkheden.

vorige artikel Teledermatologie

volgende artikel Erratum to: Diagnostiek, behandeling en nazorg van het basaalcelcarcinoom

Evidence-based Richtlijn Basaalcelcarcinoom (Modulaire update 2015).

Holterhues C, Vries E de, Louwman MW, Koljenovic S, Nijsten T. Incidence and trends of cutaneous malignancies in the Netherlands, 1989–2005. J Invest Dermatol. 2010;130(7):1807–12. CrossRefPubMed

Flohil SC, Vries E de, Neumann HA, Coebergh JW, Nijsten T. Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta Derm Venereol. 2011;91(1):24–30. CrossRefPubMed

Flohil SC, Seubring I, Rossum MM van, Coebergh JW, Vries E de, Nijsten T. Trends in Basal cell carcinoma incidence rates: a 37-year Dutch observational study. J Invest Dermatol. 2013;133(4):913–8. CrossRefPubMed

Flohil SC, Tiel S van, Koljenovic S, Jaanen-van der Sanden G, Overbeek LI, Vries E de, Nijsten T. Frequency of non-histologically diagnosed basal cell carcinomas in daily Dutch practice. J Eur Acad Dermatol Venereol. 2013;27(7):907–11. CrossRefPubMed

Vries E de, Nijsten T, Louwman MW, Coebergh JW. Skin cancer epidemic in the Netherlands. Ned Tijdschr Geneeskd. 2009;153:A768. PubMed

Lo JS, Snow SN, Reizner GT, Mohs FE, Larson PO, Hruza GJ. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol. 1991;24(5 Pt 1):715–9. CrossRefPubMed

Trakatelli M, Morton CA, Nagore E, Ulrich C, Marmo V del, Peris K, Basset-Seguin N, European Dermatology Forum. Update of the guideline on basal cell carcinoma. Eur J Dermatol. 2014;24(3):312–29. PubMed

Roozeboom MH, Mosterd K, Winnepenninckx VJ, Nelemans PJ, Kelleners-Smeets NW. Agreement between histological subtype on punch biopsy and surgical excision in primary basal cell carcinoma. J Eur Acad Dermatol Venereol. 2013;27:894–8. CrossRefPubMed

10.

Russell EB, Carrington PR, Smoller BR. Basal cell carcinoma: a comparison of shave biopsy versus punch biopsy techniques in subtype diagnosis. J Am Acad Dermatol. 1999;41:69–71. CrossRefPubMed

11.

Wolberink EA, Pasch MC, Zeiler M, Erp PE van, Gerritsen MJ. High discordance between punch biopsy and excision in establishing basal cell carcinoma subtype: analysis of 500 cases. J Eur Acad Dermatol Venereol. 2013;27:985–9. CrossRefPubMed

12.

Altamura D, Menzies SW, Argenziano G, Zalaudek I, Soyer HP, Sera F, et al. Dermatoscopy of basal cell carcinoma: morphologic variability of global and local features and accuracy of diagnosis. J Am Acad Dermatol. 2010;62(1):67–75. CrossRefPubMed

13.

Mosterd K, Thissen MR, Nelemans P, Kelleners-Smeets NW, Janssen RL, Broekhof KG, et al. Fractionated 5‑aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol. 2008;159(4):864–70. CrossRefPubMed

14.

Szeimies RM, Ibbotson S, Murrell DF, Rubel D, Frambach Y, Berker D de, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8–20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol. 2008;22(11):1302–11. CrossRefPubMed

15.

Rhodes LE, Rie MA de, Leifsdottir R, Yu RC, Bachmann I, Goulden V, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol. 2007;143(9):1131–6. CrossRefPubMed

16.

Rhodes LE, Rie M de, Enström Y, Groves R, Morken T, Goulden V, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol. 2004;140(1):17–23. CrossRefPubMed

17.

Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, Miller PS, Williams HC. Surgical excision versus imiquimod 5 % cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15(1):96–105. CrossRefPubMed

18.

Loo E van, Mosterd K, Krekels GA, Roozeboom MH, Ostertag JU, Dirksen CD, et al. Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. Eur J Cancer 2014;50(17):3011–20. CrossRefPubMed

19.

Chren MM, Torres JS, Stuart SE, Bertenthal D, Labrador RJ, Boscardin WJ. Recurrence after treatment of nonmelanoma skin cancer: a prospective cohort study. Arch Dermatol. 2011;147(5):540–6. CrossRefPubMedPubMedCentral

20.

Mosterd K, Krekels GA, Nieman FH, Ostertag JU, Essers BA, Dirksen CD, et al. Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5‑years’ follow-up. Lancet Oncol. 2008;9(12):1149–56. CrossRefPubMed

21.

Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5‑year follow-up. J Am Acad Dermatol. 2005;53(3):4–7.

22.

Silverman MK, Kopf AW, Grin CM, Bart RS, Levenstein MJ. Recurrence rates of treated basal cell carcinomas. Part 2: Curettage-electrodesiccation. J Dermatol Surg Oncol. 1991;17(9):720–6. CrossRefPubMed

23.

Kopf AW, Bart RS, Schrager D, Lazar M, Popkin GL. Curettage-electrodesiccation treatment of basal cell carcinomas. Arch Dermatol. 1977;113(4):439–43. CrossRefPubMed

24.

Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 2006;6(7):535–45. CrossRefPubMedPubMedCentral

25.

Arits AH, Mosterd K, Essers BA, Spoorenberg E, Sommer A, Rooij MJ de, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013;14(7):647–54. CrossRefPubMed

26.

Roozeboom MH, Arits AH, Nelemans PJ, Kelleners-Smeets NW. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. Br J Dermatol. 2012;167:733–56. CrossRefPubMed

27.

Roozeboom MH, Arits AH, Mosterd K, Sommer A, Essers BA, Rooij MJ de, et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. J Invest Dermatol. 2016;136(8):1568–74. CrossRefPubMed

28.

Krema H, Herrmann E, Albert-Green A, Payne D, Laperriere N, Chung C. Orthovoltage radiotherapy in the management of medial canthal basal cell carcinoma. Br J Ophthalmol. 2013;97(6):730–4. CrossRefPubMed

29.

Kwan W, Wilson D, Moravan V. Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys. 2004;60(2):406–11. CrossRefPubMed

30.

Khan L, Choo R, Breen D, Assaad D, Fialkov J, Antonyshyn O, et al. Recommendations for CTV margins in radiotherapy planning for non melanoma skin cancer. Radiother Oncol. 2012;104(2):263–6. CrossRefPubMed

31.

Cognetta AB, Howard BM, Heaton HP, Stoddard ER, Hong HG, Green WH. Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients. J Am Acad Dermatol. 2012;67(6):1235–41. CrossRefPubMed

32.

Olschewski T, Bajor K, Lang B, Lang E, Seegenschmiedt MH. Radiotherapy of basal cell carcinoma of the face and head: importance of low dose per fraction on long-term outcome. J Dtsch Dermatol Ges. 2006;4(2):124–30. CrossRefPubMed

33.

Silva JJ, Tsang RW, Panzarella T, Levin W, Wells W. Results of radiotherapy for epithelial skin cancer of the pinna: the Princess Margaret Hospital experience, 1982–1993. Int J Radiat Oncol Biol Phys. 2000;47(2):451–9. CrossRefPubMed

34.

Van Hezewijk M, Creutzberg CL, Putter H, Chin A, Schneider I, Hoogeveen M, et al. Efficacy of a hypofractionated schedule in electron beam radiotherapy for epithelial skin cancer: analysis of 434 cases. Radiother Oncol. 2010;95(2):245–9. CrossRefPubMed

35.

Zagrodnik B, Kempf W, Seifert B, Muller B, Burg G, Urosevic M, et al. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2. Cancer 2003;98(12):2708–14. CrossRefPubMed

36.

Duinkerken CW, Lohuis PJ, Heemsbergen WD, Zupan-Kajcovski B, Navran A, Hamming-Vrieze O, et al. Orthovoltage for basal cell carcinoma of the head and neck: excellent local control and low toxicity profile. Laryngoscope 2016;126(8):1796–802. CrossRefPubMed

37.

Bessems P. The cryosurgical open-cone-spray method. Proefschrift. Maastricht: Maastricht University; 1989.

38.

Wang I, Bendsoe N, Klinteberg CA, Enejder AM, Andersson-Engels S, Svanberg S, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol. 2001;144(4):832–40. CrossRefPubMed

39.

Hall VL, Leppard BJ, McGill J, Kesseler ME, White JE, Goodwin P. Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. Clin Radiol. 1986;37(1):33–4. CrossRefPubMed

40.

Bath-Hextall F, Bong J, Perkins W, Williams H. Interventions for basal cell carcinoma of the skin: systematic review. BMJ. 2004;329(7468):705. CrossRefPubMedPubMedCentral

41.

Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5 % cream. J Am Acad Dermatol. 1999;41(6):1002–7. CrossRefPubMed

42.

Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50(5):722–33. CrossRefPubMed

43.

Geisse JK, Rich P, Pandya A, Gross K, Andres K, Ginkel A, et al. Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002;47(3):390–8. CrossRefPubMed

44.

Gollnick H, Barona CG, Frank RG, Ruzicka T, Megahed M, Tebbs V, et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5 % cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol. 2005;15(5):374–81. PubMed

45.

Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox TL, et al. Imiquimod 5 % cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol. 2001;44(5):807–13. CrossRefPubMed

46.

Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrandiz C, Garcia DA, et al. Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152(5):939–47. CrossRefPubMed

47.

Shumack S, Robinson J, Kossard S, Golitz L, Greenway H, Schroeter A, et al. Efficacy of topical 5 % imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol. 2002;138(9):1165–71. CrossRefPubMed

48.

Sterry W, Ruzicka T, Herrera E, Takwale A, Bichel J, Andres K, et al. Imiquimod 5 % cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol. 2002;147(6):1227–36. CrossRefPubMed

49.

Dreier J, Felderer L, Barysch M, Rozati S, Dummer R. Basal cell carcinoma: a paradigm for targeted therapies. Expert Opin Pharmacother. 2013;14(10):1307–18. CrossRefPubMed

50.

Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164–72. CrossRef

51.

Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008;8(10):743–54. CrossRefPubMedPubMedCentral

52.

Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008 Oct;8(10):743–54.SmPC Erivedge, 22 mei 2014.

53.

Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70:60–9. CrossRefPubMed

54.

Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9. CrossRefPubMedPubMedCentral

55.

Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol. 2000;136(12):1524–30. CrossRefPubMed

56.

Iersel CA van, Velden HV van de, Kusters CD, Spauwen PH, Blokx WA, Kiemeney LA, Gerritsen MJ. Prognostic factors for a subsequent basal cell carcinoma: implications for follow-up. Br J Dermatol. 2005;153(5):1078–80. CrossRefPubMed

57.

Flohil SC, Leest RJ van der, Arends LR, Vries E de, Nijsten T. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. Eur J Cancer 2013;49(10):2365–75. CrossRefPubMed

Titel: Diagnostiek, behandeling en nazorg van het basaalcelcarcinoom
Auteurs: Drs. Esther Burkink
Dr. Nicole W. J. Kelleners-Smeets
Publicatiedatum: 10-01-2017
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Bijblijven / Uitgave 2/2017
Print ISSN: 0168-9428
Elektronisch ISSN: 1876-4916
DOI: https://doi.org/10.1007/s12414-016-0204-8

Bohn Stafleu van Loghum

Tip

Swipe om te navigeren naar een ander artikel

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 2/2017

Redactioneel ten geleide

Maligne melanoom en voorstadia

Het plaveiselcelcarcinoom en de voorstadia

Enkele zeldzame en maligne huidtumoren: M. Paget, cutaan lymfoom en het kaposisarcoom

De rol van de huisarts in de zorg voor huidkankerpatiënten

Teledermatologie